0000000000413613

AUTHOR

Mario Toti

showing 2 related works from this author

Risk Factors and Outcome among a Large Patient Cohort with Community-Acquired Acute Hepatitis C in Italy

2006

Background The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated. Methods To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis C during 1999-2004. The patients were from 12 health care centers throughout the country, and they were followed up for a mean (+/- SD) period of 14+/-15.8 months. Biochemical liver tests were performed, and HCV RNA levels were monitored. Result…

AdultMaleMicrobiology (medical)medicine.medical_specialtyHepatitis C virusHepacivirus.medicine.disease_causeAsymptomaticMED/17 Malattie infettiveRisk FactorsInternal medicineEpidemiologyHumansMedicineRisk factorHepatitisbusiness.industryTransmission (medicine)Hepatitis CMiddle Agedmedicine.diseaseHepatitis CCommunity-Acquired InfectionsChronic infectionInfectious DiseasesItalyAcute DiseaseImmunologyFemalemedicine.symptombusinessClinical Infectious Diseases
researchProduct

Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop

2011

Abstract The Italian recommendations for the therapy of hepatitis B virus (HBV)-related disease were issued in 2008. Subsequently in 2008 the nucleotide analogue (NA) Tenofovir was approved for antiviral treatment. The introduction of this important new drug has called for the current guidelines update, which includes some additional revisions: (a) the indication for therapy is extended to mild liver fibrosis and the indication for treatment is graded as “possible”, “optional” or “mandatory” according to the fibrosis stage; (b) two different treatment strategies are described: first line definite duration treatment with interferon, long-term treatment of indefinite duration with NA; (c) the…

Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCirrhosisCarcinoma HepatocellularOrganophosphonateschronic hepatitis B The Italian recommendations for the therapy of hepatitis B Tenofovir Adefovir Cirrhosis Telbivudine Lamivudine Entecavirmedicine.disease_causeAntiviral Agentsadefovir; cirrhosis; entecavir; hbv; lamivudine; telbivudine; tenofovirHepatitis B ChronicInternal medicineTelbivudinemedicineAdefovirHBVHumansStage (cooking)TenofovirHepatitis B virusHepatologybusiness.industryAdenineLiver NeoplasmsGastroenterologyLamivudineEntecavirmedicine.diseaseVirologyItalyHepatocellular carcinomaReverse Transcriptase InhibitorsInterferonsbusinessmedicine.drug
researchProduct